Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974697 | 0.87 | ATM (0.52) | F10PRSS1HPGDNPC1LMNA | |
| SCHEMBL19974941 | 0.86 | POLB (0.51) | F10PRSS1KCNH2CACNA1IALDH1A1 | |
| SCHEMBL19975275 | 0.86 | F10 (0.47) | F10PRSS1ALDH1A1LMNAMEN1 | |
| SCHEMBL28316681 | 0.84 | F10 (0.53) | F10PRSS1 | |
| SCHEMBL21183512 | 0.82 | P2RX7 (0.43) | F10PRSS1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL19974729 | 0.81 | ALDH1A1 (0.50) | F10PRSS1ALDH1A1LMNAMEN1 | |
| SCHEMBL19975354 | 0.81 | ALDH1A1 (0.53) | F10PRSS1ALDH1A1LMNAMEN1 | |
| SCHEMBL19975568 | 0.81 | KCNH2 (0.51) | F10PRSS1KCNH2CACNA1IHPGD | |
| SCHEMBL21176167 | 0.80 | ALDH1A1 (0.55) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL19975144 | 0.80 | MAPK14 (0.49) | F10PRSS1HPGDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | F10 1167/4885PRSS1 347/4885KCNH2 3665/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | F10 1141/4885PRSS1 433/4885KCNH2 3368/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | F10 1167/4885PRSS1 347/4885KCNH2 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.